Company Overview
About Solve Therapeutics
Solve Therapeutics develops antibody-drug conjugates (ADCs) using its proprietary CloakLink technology — which reduces the hydrophobicity and systemic toxicity that are the two primary causes of ADC clinical failure. The company raised $120 million in an oversubscribed financing round in November 2025, with Merck & Co. making a direct equity investment (rather than a typical licensing deal), bringing total funding to $321 million. Two ADC programs (SLV-154 and SLV-324) are in active Phase 1b trials in solid tumor patients.
Business Model & Competitive Advantage
Merck's direct equity investment is the most significant commercial signal for Solve: Merck is the manufacturer of Keytruda (pembrolizumab) — the highest-revenue cancer drug in history — and actively acquires or partners oncology assets that complement its checkpoint inhibitor franchise. An equity investment (rather than an upfront milestone deal) signals Merck's intent to participate in Solve's value creation through ownership rather than a defined asset purchase.
Competitive Landscape 2025–2026
The ADC field has become one of the most active areas of oncology drug development following the success of Enhertu (trastuzumab deruxtecan), but the leading failure modes — systemic toxicity from hydrophobic linker-payloads and off-target binding — have limited many ADC programs. CloakLink's hydrophobicity reduction addresses these issues architecturally, potentially enabling therapeutic windows for tumor targets that hydrophobic ADC chemistries cannot safely reach.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Solve Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Solve Therapeutics has achieved $120M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Solve Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Solve Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Solve Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Solve Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →